Atlas Trials

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Clinical trial NCT07576725 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07576725
Sponsor
Fred Hutchinson Cancer Center
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8Hodgkin LymphomaKaposi SarcomaMetastatic Acral Lentiginous MelanomaMetastatic Basal Cell CarcinomaMetastatic Cervical CarcinomaMetastatic Clear Cell Renal Cell CarcinomaMetastatic Colorectal CarcinomaMetastatic Cutaneous Melanoma
Start date
2026-09-01
Primary completion
2029-08-31
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.